Eli Lilly and Co (XPAR:LLY)
€ 98 0 (0%) Market Cap: 97.40 Bil Enterprise Value: 120.42 Bil PE Ratio: 113.74 PB Ratio: 61.32 GF Score: 79/100

Eli Lilly and Co to Discuss ADA Presentations and Diabetes Portfolio Transcript

Jun 10, 2019 / 02:00PM GMT
Release Date Price: €102 (-2.86%)

Jun 10, 2019 / 02:00PM GMT
Presentations and Diabetes Portfolio
Jun 10, 2019 / 02:00PM GMT

=====================
Corporate Participants
=====================
* Brad Woodward
Eli Lilly and Company - Senior Medical Director of Lilly Diabetes & Incretins Platform Team Leader
* Enrique A. Conterno
Eli Lilly and Company - Senior VP & President of Lilly Diabetes and Lilly USA
* Ilya Yuffa
Eli Lilly and Company - VP US Diabetes
* Jeff Emmick
Eli Lilly and Company - VP Diabetes Product Development
* Mike Czapar
Eli Lilly and Company - Investor Relations

=====================
Conference Call Participants
=====================
* Andrew Simon Baum
Citigroup Inc, Research Division - Global Head of Healthcare Research and MD
* Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst
* Damien Conover
Morningstar Inc., Research Division - Sector Director and Equities Strategist
* David Reed Risinger
Morgan Stanley, Research Division - MD in Equity

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot